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Abstract
Background: Chlamydia trachomatis (CT), the most common bacterial sexually transmitted infection (STI) among
young women, can result in serious sequelae. Although the course of infection is often asymptomatic, CT may
cause pelvic inflammatory disease (PID), leading to severe complications, such as prolonged time to pregnancy,
ectopic pregnancy, and tubal factor subfertility. The risk of and risk factors for complications following CT-infection
have not been assessed in a long-term prospective cohort study, the preferred design to define infections and
complications adequately.
Methods: In the Netherlands Chlamydia Cohort Study (NECCST), a cohort of women of reproductive age with and
without a history of CT-infection is followed over a minimum of ten years to investigate (CT-related) reproductive
tract complications. This study is a follow-up of the Chlamydia Screening Implementation (CSI) study, executed
between 2008 and 2011 in the Netherlands. For NECCST, female CSI participants who consented to be approached
for follow-up studies (n = 14,685) are invited, and prospectively followed until 2022. Four data collection moments are
foreseen every two consecutive years. Questionnaire data and blood samples for CT-Immunoglobulin G (IgG)
measurement are obtained as well as host DNA to determine specific genetic biomarkers related to susceptibility and
severity of infection. CT-history will be based on CSI test outcomes, self-reported infections and CT-IgG presence.
Information on (time to) pregnancies and the potential long-term complications (i.e. PID, ectopic pregnancy
and (tubal factor) subfertility), will be acquired by questionnaires. Reported subfertility will be verified in
medical registers. Occurrence of these late complications and prolonged time to pregnancy, as a proxy for
reduced fertility due to a previous CT-infection, or other risk factors, will be investigated using longitudinal
statistical procedures.
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Discussion: In the proposed study, the occurrence of late complications following CT-infection and its risk factors will
be assessed. Ultimately, provided reliable risk factors and/or markers can be identified for such late complications. This
will contribute to the development of a prognostic tool to estimate the risk of CT-related complications at an early
time point, enabling targeted prevention and care towards women at risk for late complications.
Trial registration: Dutch Trial Register NTR-5597. Retrospectively registered 14 February 2016.
Keywords: Chlamydia trachomatis, Pelvic inflammatory disease, Tubal factor subfertility, Ectopic pregnancy, Host
genetic biomarkers, Serology, The Netherlands
Background
Chlamydia trachomatis (CT) is the most commonly
reported bacterial sexually transmitted infection (STI) in
the Netherlands [1]. In contrast to most other STIs, CT is
prevalent in a large segment of the population [2]. In the
Netherlands, the reporting rate of CT-infections has stead-
ily increased from 2.7/1000 persons in 2010 to 3.1/1000 in
2014, based on data from STI clinics and general practi-
tioners (GPs). This is mainly due to increased testing rates
in high-risk groups [1]. Enhanced testing in the Netherlands
- as performed in the population-based Chlamydia Screen-
ing Implementation (CSI) study with annual screening be-
tween 2008 and 2011 - did not demonstrate a (cost-)
effective reduction of CT prevalence, related to the
relatively low and declining participation rates in the
trial [3–5]. Observational studies in other European
countries and a large CT screening pilot via general practi-
tioners in Australia, showed similar results [6, 7]. In
addition, in countries that have active screening policies
(e.g. UK and USA) the number of CT-diagnoses in the
population targeted for routine annual screening did not
decline [6, 8]. New strategies for CT control are urgently
needed.
Women bear a disproportional burden of CT-infections
[9]. In the Netherlands, prevalence of CT around 2010 was
estimated at 2.9% among 16–25 year-old women [5]. Since
CT-infections in women have an asymptomatic course in
up to 70% of the cases, most of these women will remain
untreated [10, 11]. Meanwhile the CT-infection can ascend
to the upper genital tract, resulting in pelvic inflammatory
disease (PID), potentially causing tubal damage. Tubal dam-
age in its turn may lead to ectopic pregnancy and tubal
factor subfertility [12]. These complications only become
apparent when women try to become pregnant, often
several years after an initial CT-infection that may have
gone unnoticed. A prior CT-infection may also prolong
time to pregnancy in women without any visible tubal path-
ology, due to damage to the tubal mucosa (compromising
embryo transport) or unfavourable effects in the endomet-
rium (affecting implantation) [13].
The proportion of women experiencing CT-complications
is largely unknown due to the asymptomatic nature of the
infection, delayed awareness of the actual pathology, and the
long follow-up period needed before complications become
apparent [14]. Current risk estimates range widely; the
estimated risk of PID following a CT-infection ranges be-
tween 0.5% and 72% depending on the study population
and the definitions used [15–20]. Subfertility as a result of
prior CT-infection is estimated to occur in 0.1–6% of
women infected [15, 21], and 0–1% of women with a prior
infection may develop an ectopic pregnancy [22, 23]. In a
large retrospective population-based cohort of 500,000
women aged 15–44 years in Denmark, the risk of PID,
ectopic pregnancy and tubal factor subfertility was
found to be at least 30% higher in women who had
tested CT-positive in the past compared to women who
had only negative tests. In addition, repeated diagnoses
of CT-infections increased the risk of PID by 22% [24].
Recent estimates by Price et al. in the UK, based on
results of major studies and study designs, suggest that
20% of PIDs, 5% of ectopic pregnancies, and 30% of
tubal factor subfertility cases are attributable to CT
women aged 16–44 years [25].
Rather than attempting to trace and treat all CT-in-
fections, it might be more effective to pursue second-
ary prevention in women at higher risk for
complications. Host genetic biomarkers are considered
to play a role in the development of complications in
the reproductive tract after CT-infection [26]. In
Gambian twin pairs, Bailey et al. found that 40% of
the host response to trachoma (i.e. a tropical eye in-
fection caused by CT serovar A or B) is linked to
host genetic characteristics [27]. The scarring of the eye
and the scarring of the tubes have a remarkable immuno-
genetic resemblance [26], and therefore we hypothesize a
similar effect of host genetics in CT-related trachoma and
tubal pathology. Subsequently, the presence of Single
Nucleotide Polymorphisms (SNPs) in genes, identified by
candidate gene studies and Genome Wide Association
Studies (GWAS), has already been shown to be related to
the development of tubal pathology following CT-infection.
For example, carriage of two or more SNPs in toll-like
receptor (TLR)9, TLR4, cluster of differentiation (CD)14
and caspase recruitment domain (CARD)15/nucleotide
oligomerisation domain (NOD)2 increased the risk of tubal
pathology following CT-infection from 33% to 73%, though
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the increase was not statistically significant [28]. Fur-
thermore, carriership of mannose binding lectin
(MBL) Codon 54 allele B was higher among CT-posi-
tives with tubal pathology (OR 3.9, 95%CI 1.9–8.2)
[29] than among CT-positive controls and carriage of
the NOD1 + 32,656 GG insertion was more frequent
in women with TFI compared to women without TFI
(OR 2.3, 95%CI 1.1–4.7) [30].
A range of other (host) factors such as clinical symp-
toms, co-infections, re-infections and sexual risk behav-
iour may influence the development of complications
in women with a previous CT-infection [24, 31–33].
Some factors related to the (severity of ) infection or
sexual behavioural are time-dependent. To precisely
quantify the risk and predisposing risk factors of PID,
ectopic pregnancy and tubal factor subfertility following
a CT-infection, prospective studies are needed to
provide vital data for programs to prevent CT-infection
and complications [14]. Therefore, the NEtherlands
Chlamydia Cohort STudy (NECCST) was initiated. The
strength of the study is its prospective design because this
enables to collect, at regular time intervals, questionnaire-
data with minimum (recall) bias, facilitates more extensive
time analysis and allows to directly asses the risk of CT-re-
lated complications. The final aim will be to identify
women most at risk for developing complications, in order
to introduce targeted preventive measures and strategies to
prevent CT (re-)infections in women at high risk for com-
plications. Here we describe the NECCST cohort study
design.
Methods
Study aim
With NECCST, we aim to gain more insight in late com-
plications of CT-infections in women, and to identify
women most at risk to develop CT-related complica-
tions. In this cohort study, the following aims will be
addressed:
Primary objective:
 To quantify the incidence of PID, ectopic pregnancy
and tubal factor subfertility and compare time to
pregnancy in women with and without a previous
CT-infection, in order to estimate the inherent risk
of these outcomes by a previous CT-infection.
Secondary objectives:
 To explore which combination of host genetic
biomarkers are able to distinguish women with a
high risk of developing CT-related complications
from women with a low risk of developing these
complications.
 To determine demographic, behavioural, serological
and infection-related factors that are associated with
reproductive tract complications due to a preceding
CT-infection.
Design
NECCST is a long-term (10–14 years) cohort study, of
women of reproductive age who previously participated
in the CSI study.
Setting
The starting point of the NECCST cohort is retrospective,
at entry in the CSI study conducted between 2008 and
2011 in Amsterdam, Rotterdam and South Limburg (the
Netherlands). In CSI, over 420,000 sexually active young
adults (16–29 years old) who were registered in the muni-
cipal population registers of three areas (Amsterdam,
Rotterdam and South-Limburg) were invited for annual
CT-testing by home-based self-collection of a vaginal
swab or urine sample. The samples were tested for a
CT-infection using nucleic acid amplification tests
(NAAT). In addition, participants completed question-
naires concerning demographic factors, sexual behaviour
and previous STIs. Altogether, 80,000 people (19% of
those invited) participated in CSI. Compared to non-
responders, CSI participants were more often women,
older (20–29 years), had a higher education, and were
more often of a Dutch background. For the NECCST
cohort, invitees were further selected from this group [4].
Study population
All women who participated in at least one round of the
CSI study (n = 58,818, 26% of those invited) and who
gave informed consent to be approached for future STI-
related research (14,685, 25%), are invited for participa-
tion in NECCST. Of the eligible women, 2371 (16%) had
a positive CT-history (i.e. PCR positive result and/or
self-reported CT-infection during CSI) and 12,314 (84%)
had a negative CT-history according to CSI data (PCR
negative and no self-reported previous CT-infection).
These women are traced in the Dutch municipal
registers and invited for participation in NECCST. Par-
ticipants are between 20 and 38 years of age at the first
data collection moment, and will be between 27 and
44 years of age by the end of NECCST. Women are cen-
sored when they have emigrated from the Netherlands
or when contact details cannot be retrieved from the
municipal registers for other reasons.
Study procedures
NECCST covers a minimal individual follow-up period
of 10 years and a maximum of 14 years, depending on
inclusion in CSI, onwards. Participants will be contacted
four times until 2022.
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In 2015/2016, women were informed by regular mail and
email (when available from CSI) about NECCST, and re-
ceived an invitation letter and an information brochure. Via
a web link in the invitation letter women could decline or
accept participation. After one month a reminder is sent.
After accepting, participating women were requested to
complete an online informed consent form for participation
in NECCST.
The first data collection moment includes an electronic
questionnaire followed by a test kit for self-collection of
blood by a finger-prick for CT IgG analyses. Host DNA is
obtained by either using the stored CSI vaginal swabs or
urine, or via additional newly self-collected buccal swabs
[Copan FLOQSwabs™, Copan diagnostics, USA]. Every two
years, an online questionnaire will be sent by email. In
2022, at the last data collection moment, a second test kit
for self-collection of blood will be sent for CT IgG analyses
(Fig. 1, study flowchart).
Data collection during NECCST
Questionnaires
At the start of the NECCST follow-up period, women
were asked to complete a baseline questionnaire.
Thereafter, they receive a follow-up online question-
naire once every two years. The questionnaires
inquire data about recent and past CT-infections and
CT-related PID, time to pregnancy, ectopic pregnancy,
and fertility problems. In addition, questionnaires will
address demographic factors, age, ethnicity, educa-
tional level, sexual behaviour, other STIs, contracep-
tive use and health characteristics (e.g. smoking,
weight changes, chronic pelvic pain (abdominal pain
with a duration of 6 months or more) and previous
abdominal surgery). Questionnaires are all electronic,
sent with Formdesk [Formdesk, Wassenaar, The
Netherlands], which creates a database automatically,
linkable to other data sources (i.e. CSI-database), by
individual participant number.
Medical register check
All women who report subfertility are asked add-
itional informed consent to allow us to approach their
GPs and/or fertility clinics to provide specified, de-
tailed information regarding the cause of subfertility
from the patient’s files in medical registers.
Fig. 1 Flowchart of the study. *In case subfertility is reported, the participants’ medical files will be requested to verify the cause of subfertility.
CSI = Chlamydia Screening Implementation. NECCST = Netherlands Chlamydia Cohort Study. CT = Chlamydia trachomatis. PCR = Polymerase chain
reaction. IgG = Immunoglobulin G. CT-positive = at least one positive outcome, either a positive CSI CT Polymerase Chain Reaction (PCR) result, a
self-reported CT-infection or CT IgG presence. CT-negative = Never tested positive during CSI, no self-reported CT-infection and no CT IgG presence
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Chlamydia trachomatis serology
A test kit will be sent to participants to collect a capillary
blood sample at home in a collection tube [BD Microtainer
serum separator tube, Becton, Dickinson and Company,
USA] and to return it to the laboratory in the accompany-
ing packaging. All returned samples are immediately proc-
essed and blood collection tubes are centrifuged to collect
serum. Serum samples are stored at −20 °C until an ELISA
assay is performed. CT IgG antibodies are measured using
a peptide based ELISA test [Medac CT IgG pELISA,
Wedel, Germany] with minimal cross-reactivity and high
throughput [34]. CT IgG antibody test results will be used
as a marker for a previous CT-infection which remained
unnoticed [35]. In addition, the seroconversion rate will be
analysed in women with a previously self-reported or PCR
confirmed CT-infection. An additional IgG antibody test
will be performed in 2022, in order to determine new infec-
tions occurring during the study period and to gain insight
in persistence of CT IgG levels over time.
Host genetic biomarkers
Host genetic biomarkers (SNPs), will be determined
from host material obtained from vaginal swabs and
urine samples collected during the CSI study and stored
in a biobank. DNA will be extracted and host genetic
biomarkers will be analysed using Kompetitive Allele
Specific PCR (KASP) technology, utilizing a unique form
of competitive allele-specific polymerase chain reaction
(PCR). This enables accurate scoring of SNPs, inserts or
deletions [36]. A selection of 50–100 SNPs will be
tested. This SNP panel is based on previous research,
that showed a potential association with chlamydia sus-
ceptibility and risk to develop complications after infec-
tion [26]. From participants whose previous CSI study
sample is not available or of insufficient quality, a buccal
swab sample is obtained at the start of NECCST in order
to obtain DNA.
Defining CT-history
As CT-infections often go unnoticed it was decided to
define a positive CT-history based on one of the follow-
ing three outcomes, either a self-reported CT-infection,
positive PCR-test outcome in the CSI study or the presence
of CT IgG antibodies in serum. Combining these three
outcomes will reduce misclassification of CT-history.
Power calculation
In total 14,685 women are invited of whom 2371 had a
positive CT-history and 12,314 had a negative CT-history
recorded in the CSI study. Assuming a high response rate
of 60% (due to previous informed consent), a cross-over
rate of 12% from negative to positive CT-history and an
estimated loss to follow up of 25% until 2022, we expect
to have 1700 women with a positive CT-history and 4900
with a negative CT-history participating in NECCST until
the end of the study in 2022. Power calculations, based on
the primary aim were performed using risk estimates from
modelling and observational studies. In women with a
positive CT-history the following risk estimates were
taken into account: 10% for developing PID, 0.5% for
ectopic pregnancy and 2% for tubal factor subfertility
[15, 22, 23]. In women with a negative CT-history, the
risk to develop these complications was estimated to be
0.5% for PID [37], and 0.05% for tubal factor subfertility
[15]. For ectopic pregnancy, the expected risk ranges
between 0 and 1% in CT negatives [22, 23]. Expected cu-
mulative prevalence’s of these complicates were calculated
based on age at the end of NECCST in 2022 (Table 1).
The expected sample size of the study population, i.e.
1700 women with a positive CT-history and 4900 women
with a negative CT-history, is sufficient to detect sig-
nificant differences (p < 0.05) in risks of CT-related
complications between women with and without a
positive CT-history with a power of 85%–99%.
Data analysis and statistics
Data from the CSI-study will be merged with data from
NECCST. Data quality will be assessed, in particular the
potential for bias due to non-response and the extent of
missing data. Incidence rates, calculated as the number
of new cases divided by the total person-time at risk, of
the primary study endpoints PID, ectopic pregnancies
and tubal factor subfertility will be compared between
women with and without a positive CT-history. Person-
Table 1 Power calculation per outcome variable
Expected cumulative prevalence
in 2022
Number of samples needed
for 80% power
Expected power with samples
size N = 6600
CT pos. History CT neg. History CT pos. History CT neg. History CT pos. History (n = 1700) CT neg. History (n = 4900)
PID 7.7% 1.1% 63 195 >99%
Ectopic pregnancy 1.8% 0.9% 1415 4385 85%
Tubal factor subfertility 1.3% 0.2% 401 1241 >99%
Expected cumulative prevalence of PID, ectopic pregnancy and tubal factor subfertility was based on age distribution per outcome in the primary care database
from the Netherlands Institute for Health Services Research (NIVEL – PCD) and the expected age distribution in NECCST in 2022 by CT status. Here from we
derived the samples size, with 80% power, a significance level of 5% and a 1 to 3 exposed/unexposed ratio, per outcome in the CT-positive history and negative
history group in 2022 (http://www.openepi.com). CT Chlamydia trachomatis infection, PID pelvic inflammatory disease
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time at risk is calculated from the time point a woman
becomes sexually active (assessed from the CSI ques-
tionnaire) and ends at the time of an event. In case of
no event, person-time at risk stops at the end of partici-
pation, migration out of the Netherlands or the end of
the study period, whichever comes first.
Each of the primary study endpoints PID, ectopic
pregnancy and tubal factor subfertility will be analysed
for women with and without a positive CT-history
using Kaplan-Meier plots and log-rank test. Cox pro-
portional hazards regression analyses will be performed
to calculated hazard ratios, in which CT-history is
included as a time-dependent variable. Once a partici-
pant becomes CT-positive, the participant switches
over to the CT-positive group. We will explore if time
to infection for women with a positive CT-history
based only on their CT IgG presence without further
information on the time of infection, can be estimated
using information from the group with both a positive
IgG test result and a positive PCR test or self-reported
CT-infection. To account for confounding and effect
modification, co-factors such as age, educational level,
host genetic biomarkers, demographics, behavioural
and infection characteristics (i.e. as previous treatment
and other STI’s), will be included in the model.
Similar analyses will be done to assess the factors re-
lated to time to pregnancy. For time to pregnancy the
follow-up period is defined as the time in months be-
tween the moment the woman reports starting to try to
conceive until the start of pregnancy, or (if not pregnant)
the date of completion of the questionnaire.
Univariate and multivariate Cox regression analyses
will also be applied to investigate covariates among
women with a positive CT-history and the event of a
PID, ectopic pregnancy or tubal factor subfertility. All
factors that are significantly associated with the specific
complication will be included in a multivariate Cox pro-
portional hazards regression model. Using backward
stepwise selection, factors that are not associated with
the development of the complication anymore (with a
threshold p-value of 0.1) will be removed. All other
factors will be assigned significantly associated with the
development of the complication. The following
literature-based variables will be selected as a potential
predictor: age, educational level, host genetic bio-
markers, and demographic, behavioural and infection
characteristics.
Sensitivity analyses will be performed by varying the def-
initions of a positive CT-history, i.e. only CSI-PCR positive
outcomes compared to self-reported CT-infections and
CT IgG positivity. We will also perform sensitivity ana-
lyses on variable definition of outcome variables, such as
planned versus unplanned pregnancies and confirmed
versus unconfirmed tubal factor subfertility.
Discussion
In NECCST, the risk of PID, time to pregnancy, tubal fac-
tor subfertility and ectopic pregnancy after CT-infection
will be determined in a cohort of women of reproductive
age with an individual follow-up time of 10 to 14 years.
NECCST will investigate the role of a wide range of
host- and infection-specific factors in the develop-
ment of CT-related complications. Insight in risk
factors of CT-related complications may allow for a
new strategy in prevention of the complications of
CT. This could be an alternative approach in addition
to current chlamydia control strategies, aiming to test
and treat to prevent ongoing transmission. The ultim-
ate goal will be to develop a prognostic tool to iden-
tify the group of women with an enhanced risk of
complications after a CT-infection at an early time
point in their life, when (secondary) preventive mea-
sures can be effectively applied. Women at high risk
for complications could be specifically targeted for
prevention of (re-)infection, e.g. by frequent follow-up
as an optimal strategy for preventing long-term com-
plications [24].
Strengths
NECCST will be the first cohort study in which risks of
and for late complications of CT are prospectively stud-
ied during a follow-up period of more than 10 years. A
prospective study design allows for a clear temporal
sequence of exposure and outcome and examination of
multiple effects of a single exposure while avoiding
selection bias at enrolment. The long-term follow-up is
needed to examine the relation between exposure and
outcome, as CT-infections are often acquired below the
age of 20, fertility problems will only become apparent
when a woman tries to become pregnant, which is often
in her late twenties or thirties.
This cohort combines several data sources: histor-
ical data from the CSI, newly acquired questionnaire
data at four time points during NECCST, medical
register data, serological outcomes and host genetic
biomarkers. By combining information from tests
from the CSI study, self-reported CT-infections and
CT IgG status, we expect to obtain a more complete
picture of previous CT-infections than in most other
studies. As we make use of serology, we will also be
able to identify women who had a CT-infection which
remained unnoticed and was therefore left untreated.
These women can be compared to women who tested
positive for CT and were treated accordingly. Com-
paring these groups may give us more insight into
the IgG status and risk of CT-related complications
between treated and untreated women and allow us
to study the natural course of a CT-infection [14].
Hoenderboom et al. BMC Infectious Diseases  (2017) 17:264 Page 6 of 9
Host genetic biomarkers are nowadays implemented in
prediction models and health care systems. Developing a
set of specific genetic biomarkers associated with a high
risk for CT-related complications can facilitate identify-
ing the group of women most vulnerable for developing
complications [26, 38]. With a ‘precision (or personal-
ized) medicine approach’ a diagnostic tool on the basis
of women’s genetic profile can be employed for selecting
the group to be targeted for specific (cost)effective inter-
ventions such as repeated CT-testing, additional treat-
ment and medical follow-up.
Limitations
Although in our study CT-history will be based on PCR
results from the CSI study, self-reported infections and
CT IgG measurements, misclassifications may still
occur. Women with an unnoticed infection may have a
negative CT IgG antibody test, because an infection not
always leads to CT IgG antibody production, or because
the levels of antibodies have waned since the time of
infection. The proportion of infected women who sero-
convert and who remain persistently seropositive is not
well established yet [35]. Sensitivity and specificity of CT
IgG measurement of the assay we will use in NECCST
(Medac pELISA) were reported to be 71.4% and 97.3% at
the time of CT-infection, respectively [39]. However,
within six months after infection, seropositivity was 66%
and after six months or longer, seropositivity decreased to
38% [40], resulting in CT-positives possibly being misclas-
sified as CT-negative. Because this could result in under-
estimation of the true association between CT-history and
complications, we will perform sensitivity analyses in
which only CSI-PCR positives will be classified as positive.
In our study, outcomes such as PID, tubal factor sub-
fertility, ectopic pregnancy and time to pregnancy will
be (initially) based on self-reporting, which may induce
recall bias despite multiple questionnaire rounds every
two years. The diagnosis of PID is imprecise and lacks a
non-invasive accurate gold standard test [41]. Diagnostic
bias could take place towards women with a positive
CT-history [14]. This may result in a more pronounced
underestimation of the risk on PID among CT-negatives
than among CT-positives, potentially leading to an over-
estimation of the difference in PID risk between those
groups. Therefore, in de questionnaire we specifically
inquire about diagnosis by GP and hospital admissions
for PID, and recall bias will be reduced. As a rough
proxy for silent PID episodes, women are asked if they
experienced chronic pelvic pain defined as unexplained
abdominal pain with a duration of 6 months or more
[33, 42]. A range of other causes besides PID can result
in chronic pelvic pain as well. However, assuming the in-
cidences of these other causes to be evenly distributed
between CT-positives and CT-negatives, any differences
in the occurrence of chronic pelvic pain may be consid-
ered the result of PID. This will increase power and
cover both symptomatic and silent PIDs.
In participants with an asymptomatic CT-infection we
will not be able to determine when the first CT-infection
and tubal scarring that eventually leads to subfertility have
occurred. We cannot rule out that in some cases tubal
damage was already present before the CT-infection. But
in general tubal scarring may be assumed to occur after
infection.
Finally, selection bias may occur when women who
have experienced reproductive tract problems and have
had a CT-infection are more willing to participate in
NECCST. However, we expect that based on the rela-
tively young age at the inclusion in NECCST, a substan-
tial proportion of participants will not yet have tried to
become pregnant when giving their consent to partici-
pate. Nevertheless, sensitivity analyses will be performed
to compare outcomes in participants who were aware of
reproductive complications at the start of NECCST with
outcomes in those who were not yet aware.
In summary
In the future, instead of striving to detect and treat all
CT-infections, chlamydia control strategies could focus
on prevention of complications following a CT-infection.
Long-term complications in women are the most im-
portant burden of CT-infections at population level.
With this cohort study, we aim to contribute to better
insight and further understanding of the factors involved
in the development of late CT-complications, and to
identify markers to understand which women are at risk
of such complications. This should allow improved and
targeted interventions to control adverse outcomes of
CT infections.
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